IPP Bureau
Resolution Therapeutics doses first patient in phase I/II Emerald study of RTX001 for end-stage liver disease
By IPP Bureau - September 05, 2025
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
Quotient Sciences and CPI join forces to accelerate RNA drug development
By IPP Bureau - September 05, 2025
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
FDA expands medtronic MiniMed 780G system
By IPP Bureau - September 05, 2025
Now integrates with Abbott’s instinct sensor and approved for type 2 diabetes
Lupin receives FDA approval for Risperidone LAI with 180-day CGT exclusivity
By IPP Bureau - September 04, 2025
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
Aarti Pharmalabs inaugurates phase 1 of greenfield manufacturing facility
By IPP Bureau - September 04, 2025
Phase 1 has a total reactor capacity of 440 kL with 63 reactors
Caplin Steriles granted final approval for ANDA Milrinone Lactate in 5% Dextrose Injection by USFDA
By IPP Bureau - September 04, 2025
Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure
Cupid’s B2B export order book stands at Rs. 100 Cr+
By IPP Bureau - September 04, 2025
These orders are from international government tenders in South Africa, Tanzania, and Kenya, as well as from international agencies WHO/UNFPA, NGOs like MSI and PSI
Syntegon reports H1 2025 EBITDA higher by 41% to €127 million
By IPP Bureau - September 04, 2025
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Brenntag Specialties selected European distributor for Kerry’s pharmaceutical-grade acetates
By IPP Bureau - September 04, 2025
Brenntag Specialties will provide pharmaceutical manufacturers and biopharmaceutical companies with a reliable supply of high-purity, GMP-compliant acetates
Merck’s oral PCSK9 inhibitor Enlicitide shows promising results in phase 3 CORALreef lipids study
By IPP Bureau - September 04, 2025
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
Eli Lilly appoints Dr. Vivek Jha as Senior Director – Commercial Strategy, AI & Transformation
By IPP Bureau - September 03, 2025
He will be leading the design and execution of transformative strategies that harness the power of AI and automation, drive process optimization, and ignite digital innovation
Health Minister Nadda to inaugurate India MedTech Expo 2025
By IPP Bureau - September 03, 2025
The three-day expo will feature an expansive exhibition showcasing MSMEs, startups, research institutions, future innovation pavilions, state showcases, and government initiatives
iPHEX 2025: Global regulatory conclaves to highlight India’s role in shaping global health
By IPP Bureau - September 03, 2025
This year’s edition will witness participation of over 700 Indian exporters showcasing their products and services; 500+ overseas delegates representing more than 120 countries; 20,000 domestic visitors; and 8,000+ B2B meetings
Merck appoints David Weinreich as new Global Head of R&D and CMO for Healthcare Business
By IPP Bureau - September 03, 2025
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
